286 related articles for article (PubMed ID: 9119123)
21. Affinity chromatography to remove viruses during preparation of plasma derivatives.
Lawrence JE
Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
[TBL] [Abstract][Full Text] [Related]
22. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
[No Abstract] [Full Text] [Related]
23. Membrane filtration for virus removal.
Brandwein H; Aranha-Creado H
Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
[TBL] [Abstract][Full Text] [Related]
24. Detection of adventitious viruses in biologicals--a rare occurrence.
Nims RW
Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
[TBL] [Abstract][Full Text] [Related]
25. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
[TBL] [Abstract][Full Text] [Related]
26. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
27. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
28. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
Hilfenhaus J; Niedrig M; Nowak T
Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
[TBL] [Abstract][Full Text] [Related]
29. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
30. Viral safety evaluation of plasma-derived therapeutic products.
Farshid M
Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
[TBL] [Abstract][Full Text] [Related]
31. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
Roberts PL; Dunkerley C; McAuley A; Winkelman L
Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
[TBL] [Abstract][Full Text] [Related]
32. Viral safety evaluation of biopharmaceuticals and homoeopathic preparations of human or animal origin.
Immelmann A
Pharmeur Sci Notes; 2006 Aug; 2006(1):41-5. PubMed ID: 17694646
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of retroviruses in biologicals manufactured for human use.
Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
[TBL] [Abstract][Full Text] [Related]
34. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses.
Pocchiari M
Dev Biol Stand; 1991; 75():87-95. PubMed ID: 1794633
[TBL] [Abstract][Full Text] [Related]
35. Virus validation procedures: practical aspects.
Minor PD
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
[TBL] [Abstract][Full Text] [Related]
36. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
[No Abstract] [Full Text] [Related]
37. Introduction to the issues: new potential contaminants and other exogenous agents.
Albrecht P
Dev Biol Stand; 1992; 76():255-8. PubMed ID: 1478344
[No Abstract] [Full Text] [Related]
38. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
39. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
Xu Y; Brorson K
Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
[TBL] [Abstract][Full Text] [Related]
40. Viral validation of the manufacturing process of high purity albumin from placentas.
Grandgeorge M; Véron JL
Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
